Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epanova in persistent hypertriglyceridemia (ESPRIT)
NCT01408303Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Aug 2011
- Primary completion
- Jun 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of eicosapentaenoic acid + docosahexaenoic acid in hypertriglyceridemia, sponsored by AstraZeneca. Started Aug 2011; status: completed.
02
Drugs
eicosapentaenoic acid + docosahexaenoic acid
03
Conditions
hypertriglyceridemia
Beyond the preview
Go deeper on NCT01408303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01408303.